FINWIRES · TerminalLIVE
FINWIRES

Immutep Receives New US Patent for Cancer Treatment Method; Shares Down 4%

By

Immutep (ASX:IMM) obtained a fourth patent from the US Patent and Trademark Office related to its cancer treatments, according to a Tuesday filing with the Australian bourse.

The new patent, which covers methods to treat cancer by administering eftilagimod alfa in combination with PD-1 pathway inhibitors, has an expiry date of Jan. 20, 2036, per the filing.

The company is evaluating eftilagimod alfa in a variety of solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, soft tissue sarcoma, and breast cancer.

Immutep shares fell nearly 4% in recent Tuesday trade.

Related Articles

Asia

Claimants Withdraw Lawsuit Against PropNex's Arm

PropNex (SGX:OYY) said a lawsuit filed against the company's wholly-owned subsidiary, PropNex Realty, as a co-defendant, has been dropped, according to a Friday filing to the Singapore stock exchange.The claimants have discontinued and withdrawn the suit, the statement said.PropNex Realty was named as one of three co-defendants in a lawsuit filed in the High Court of Singapore in February. According to the lawsuit, claimants sought damages against PropNex Realty for alleged breach of duty of care and sought compensation of around SG$367,405 in damages.The withdrawal of the case is not expected to have any material impact on the financial position and performance of the group for the financial year ending Dec. 31.PropNex's shares were down nearly 1% in Monday's trade.

SGX:OYY
Asia

Dawning Information Industry Proposes Convertible Bond Issue for AI, Storage Push

Dawning Information Industry (SHA:603019) on Monday filed a prospectus for a convertible bond issue to unspecified investors.Proceeds are earmarked toward an artificial intelligence computing cluster system, a next-generation AI training-inference integrated machine and a domestic advanced storage system.Shares of the supercomputer manufacturer were down 1% in recent trade.

SHA:603019
Asia

Ampol Secures KKR as Cornerstone Investor in AU$400 Million Financing Transaction; Shares Up 3%

Ampol (ASX:ALD) secured a cornerstone investment from KKR in its AU$400 million financing transaction, according to a Monday statement from the investment firm.KKR is making this investment from its Asia Pacific Credit strategy and insurance platform, with support from Clifford Capital.Ampol will use the funds for refinancing initiatives and other general corporate purposes.Ampol's shares rose nearly 3% in recent trading on Monday.

ASX:ALD